{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:33:48Z","timestamp":1792679628387,"version":"4.5.0"},"reference-count":37,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>An autologous formalin-fixed tumor vaccine (AFTV) derived from resected glioblastoma (GBM) tissue can be used against unidentified tumor antigens. Thus, the authors conducted a multicenter double-blind phase IIb trial to investigate the efficacy of an AFTV.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>Eligible patients were adults with supratentorial GBMs, 16\u201375 years of age, with Karnofsky Performance Scale (KPS) scores \u2265 60%, and no long-term steroid administration. An AFTV comprising fixed paraffin-embedded tumor tissue with immune adjuvants or an identical placebo without fixed tumor tissue was injected intradermally over three courses before and after chemoradiotherapy. The primary and secondary end points were overall survival (OS), progression-free survival (PFS), and 3-year survival rate.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Sixty-three patients were enrolled. The average patient age was 61 years. The median KPS score was 80%, and the median resection rate was 95%. The full analysis set of 57 patients indicated no significant difference in OS (p = 0.64) for the AFTV group (median OS 25.6 months, 3-year OS rate 38%) compared with the placebo group (31.5 months and 41%, respectively) and no difference in PFS (median PFS 13.3 months in both groups, p = 0.98). For patients with imaging-based total tumor removal, the 3-year PFS rate was 81% in the AFTV group versus 46% in the placebo group (p = 0.067), whereas the 3-year OS rate was 80% versus 54% (p = 0.16), respectively. Similar results were obtained in the p53-negative subgroups. Severe adverse effects were not observed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>The AFTV may have potential effects in certain patient subgroups. A phase III study for patients with total tumor removal remains warranted to confirm these findings.<\/jats:p>\n<jats:p>Clinical trial registration no.: UMIN000010602 (UMIN Clinical Trials Registry)<\/jats:p>\n<\/jats:sec>","DOI":"10.3171\/2022.12.jns221221","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T11:29:59Z","timestamp":1674214199000},"page":"344-354","source":"Crossref","is-referenced-by-count":17,"title":["A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas"],"prefix":"10.3171","volume":"139","author":[{"given":"Yoshihiro","family":"Muragaki","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo;"},{"name":"Center for Advanced Medical Engineering Research and Development, Kobe University, Hyogo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Tsukuba, Ibaraki;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nitta","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soko","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komori","sequence":"additional","affiliation":[{"name":"Center for Advanced Medical Engineering Research and Development, Kobe University, Hyogo;"},{"name":"Tokyo Metropolitan Neurological Hospital, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takakazu","family":"Kawamata","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yokohama City University, Kanagawa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Proton Medical Research Center, Faculty of Medicine, University of Tsukuba, Ibaraki;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Tsukuba, Ibaraki;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kumamoto University, Kumamoto;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kumamoto University, Kumamoto;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oita University, Oita;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomo","family":"Momii","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oita University, Oita;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tohoku University, Miyagi;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tohoku University, Miyagi;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tabei","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Japan Red Cross Medical Center, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Japan Red Cross Medical Center, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Matsutani","sequence":"additional","affiliation":[{"name":"Gotanda Rehabilitation Hospital, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Karasawa","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Komagome Hospital, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Hidaka Hospital, Gunma;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Maebayashi","sequence":"additional","affiliation":[{"name":"Nihon Medical School, Tokyo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Tsukuba Clinical Research and Development Organization, University of Tsukuba, Ibaraki; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ohno","sequence":"additional","affiliation":[{"name":"Cell-Medicine Inc., Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"10","key":"b1","series-title":"N Engl J Med","first-page":"987","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ,  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u2013996.15758009"},{"issue":"23","key":"b2","series-title":"JAMA","first-page":"2306","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp R","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A,  Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306\u20132316.29260225"},{"issue":"7","key":"b3","series-title":"JAMA Oncol","first-page":"1003","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 Randomized Clinical Trial","volume":"6","author":"Reardon DA","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A,  Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(7):1003\u20131010.32437507"},{"issue":"3","key":"b4","series-title":"J Neurooncol","first-page":"375","article-title":"Combination immunotherapy strategies for glioblastoma","volume":"151","author":"Chan HY","year":"2021","unstructured":"Chan HY, Choi J, Jackson C, Lim M. Combination immunotherapy strategies for glioblastoma. J Neurooncol. 2021; 151(3):375\u2013391.33611705"},{"issue":"7463","key":"b5","series-title":"Nature","first-page":"415","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov LB","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC,  Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415\u2013421.23945592"},{"issue":"10","key":"b6","series-title":"Lancet Oncol","first-page":"1373","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller M","year":"2017","unstructured":"Weller M, Butowski N, Tran DD,  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373\u20131385."},{"issue":"5","key":"b7","series-title":"J Neurosurg","first-page":"963","article-title":"Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme","volume":"108","author":"Izumoto S","year":"2008","unstructured":"Izumoto S, Tsuboi A, Oka Y,  Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108(5):963\u2013971.18447714"},{"issue":"3","key":"b8","series-title":"J Clin Oncol","first-page":"337","article-title":"Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen\u2013A24 with recurrent or progressive glioblastoma multiforme","volume":"29","author":"Terasaki M","year":"2011","unstructured":"Terasaki M, Shibui S, Narita Y,  Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen\u2013A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol. 2011;29(3):337\u2013344."},{"issue":"3","key":"b9","series-title":"Neuro Oncol","first-page":"348","article-title":"A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita Y","year":"2019","unstructured":"Narita Y, Arakawa Y, Yamasaki F,  A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Neuro Oncol. 2019;21(3):348\u2013359.30500939"},{"issue":"3","key":"b10","series-title":"Nat Med","first-page":"267","article-title":"Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections","volume":"1","author":"Liu SQ","year":"1995","unstructured":"Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med. 1995;1(3):267\u2013271.7585045"},{"issue":"12","key":"b11","series-title":"Nat Med","first-page":"1283","article-title":"Tumor-specific autologous cytotoxic T lymphocytes from tissue sections","volume":"2","author":"Liu SQ","year":"1996","unstructured":"Liu SQ, Shiraiwa H, Kawai K,  Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nat Med. 1996;2(12):1283.8946818"},{"issue":"5","key":"b12","series-title":"Clin Cancer Res","first-page":"1574","article-title":"Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma","volume":"10","author":"Kuang M","year":"2004","unstructured":"Kuang M, Peng BG, Lu MD,  Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10(5):1574\u20131579.15014006"},{"issue":"8","key":"b13","series-title":"Cancer Sci","first-page":"1226","article-title":"Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients","volume":"98","author":"Ishikawa E","year":"2007","unstructured":"Ishikawa E, Tsuboi K, Yamamoto T,  Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci. 2007;98(8):1226\u20131233.17517052"},{"issue":"2","key":"b14","series-title":"J Neurosurg","first-page":"248","article-title":"Phase I\/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article","volume":"115","author":"Muragaki Y","year":"2011","unstructured":"Muragaki Y, Maruyama T, Iseki H,  Phase I\/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg. 2011;115(2):248\u2013255.21568657"},{"issue":"3","key":"b15","series-title":"J Neurosurg","first-page":"543","article-title":"Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma","volume":"121","author":"Ishikawa E","year":"2014","unstructured":"Ishikawa E, Muragaki Y, Yamamoto T,  Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014;121(3):543\u2013553.24995786"},{"issue":"1","key":"b16","series-title":"Biometrics","first-page":"163","article-title":"Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint","volume":"38","author":"Schoenfeld DA","year":"1982","unstructured":"Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982;38(1):163\u2013170.7082758"},{"issue":"2","key":"b17","series-title":"Eur J Cancer","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J,  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u2013247.19097774"},{"issue":"3","key":"b18","series-title":"J Neurooncol","first-page":"627","article-title":"JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon\u03b2 plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma","volume":"138","author":"Wakabayashi T","year":"2018","unstructured":"Wakabayashi T, Natsume A, Mizusawa J,  JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon\u03b2 plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol. 2018;138(3):627\u2013636.29557060"},{"issue":"1","key":"b19","series-title":"Sci Rep","first-page":"6704","article-title":"Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)","volume":"8","author":"Pandith AA","year":"2018","unstructured":"Pandith AA, Qasim I, Zahoor W,  Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). Sci Rep. 2018;8(1):6704.29712977"},{"issue":"1","key":"b20","series-title":"Cell","first-page":"188","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob F","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY,  A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188\u2013204.e22.31883794"},{"issue":"6","key":"b21","series-title":"Cancer Immunol Immunother","first-page":"707","article-title":"Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response","volume":"64","author":"Hashimoto N","year":"2015","unstructured":"Hashimoto N, Tsuboi A, Kagawa N,  Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunol Immunother. 2015;64(6):707\u2013716.25772149"},{"issue":"1","key":"b22","series-title":"J Transl Med","first-page":"142","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau LM","year":"2018","unstructured":"Liau LM, Ashkan K, Tran DD,  First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142.29843811"},{"issue":"1","key":"b23","series-title":"J Transl Med","first-page":"104","article-title":"A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients","volume":"15","author":"Inog\u00e9s S","year":"2017","unstructured":"Inog\u00e9s S, Tejada S, de Cerio AL,  A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15(1):104.28499389"},{"issue":"2","key":"b24","series-title":"Cancer Immunol Immunother","first-page":"90","article-title":"In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells","volume":"47","author":"Kim C","year":"1998","unstructured":"Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother. 1998;47(2):90\u201396.9769117"},{"key":"b25","series-title":"J Biol Chem","first-page":"100648","article-title":"Recognition of acrolein-specific epitopes by B cell receptors triggers an innate immune response","volume":"296","author":"Endo R","year":"2021","unstructured":"Endo R, Uchiyama K, Lim SY, Itakura M, Adachi T, Uchida K. Recognition of acrolein-specific epitopes by B cell receptors triggers an innate immune response. J Biol Chem. 2021;296:100648."},{"issue":"2","key":"b26","series-title":"Cancer Biol Med","first-page":"171","article-title":"Immuno-oncology combinations: raising the tail of the survival curve","volume":"13","author":"Harris SJ","year":"2016","unstructured":"Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13(2):171\u2013193.27458526"},{"issue":"8","key":"b27","series-title":"Cancer Immunol Immunother","first-page":"1219","article-title":"Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy","volume":"58","author":"van der Most RG","year":"2009","unstructured":"van der Most RG, Currie AJ, Mahendran S,  Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother. 2009;58(8):1219\u20131228.19052741"},{"issue":"3","key":"b28","series-title":"PLoS One","first-page":"e59082","article-title":"Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice","volume":"8","author":"Sanchez-Perez LA","year":"2013","unstructured":"Sanchez-Perez LA, Choi BD, Archer GE,  Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082.23527092"},{"issue":"2","key":"b29","series-title":"OncoImmunology","first-page":"e23288","article-title":"Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients","volume":"2","author":"Iversen TZ","year":"2013","unstructured":"Iversen TZ, Brimnes MK, Nikolajsen K,  Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. OncoImmunology. 2013;2(2):e23288.23525955"},{"issue":"1","key":"b30","series-title":"BMC Neurol","first-page":"282","article-title":"Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis","volume":"21","author":"Ishikawa E","year":"2021","unstructured":"Ishikawa E, Sugii N, Matsuda M,  Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis. BMC Neurol. 2021;21(1):282.34281518"},{"issue":"1","key":"b31","series-title":"J Neurosurg","first-page":"3","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai N","year":"2011","unstructured":"Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3\u20138.21417701"},{"issue":"5","key":"b32","series-title":"Ann Oncol","first-page":"1011","article-title":"Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study","volume":"25","author":"Sugiyama T","year":"2014","unstructured":"Sugiyama T, Fujiwara K, Ohashi Y,  Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. Ann Oncol. 2014;25(5):1011\u20131017.24569914"},{"issue":"6","key":"b33","series-title":"N Engl J Med","first-page":"420","article-title":"Expression of p53 and prognosis in children with malignant gliomas","volume":"346","author":"Pollack IF","year":"2002","unstructured":"Pollack IF, Finkelstein SD, Woods J,  Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420\u2013427.11832530"},{"issue":"7785","key":"b34","series-title":"Nature","first-page":"112","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel FP","year":"2019","unstructured":"Barthel FP, Johnson KC, Varn FS,  Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019;576(7785):112\u2013120.31748746"},{"issue":"3","key":"b35","series-title":"Genome Res","first-page":"316","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim H","year":"2015","unstructured":"Kim H, Zheng S, Amini SS,  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316\u2013327.25650244"},{"issue":"1","key":"b36","series-title":"Nat Commun","first-page":"352","article-title":"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy","volume":"12","author":"Gromeier M","year":"2021","unstructured":"Gromeier M, Brown MC, Zhang G,  Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021;12(1):352.33441554"},{"issue":"40","key":"b37","series-title":"Oncotarget","first-page":"64910","article-title":"Immunohistochemical correlates of TP53 somatic mutations in cancer","volume":"7","author":"Murny\u00e1k B","year":"2016","unstructured":"Murny\u00e1k B, Hortob\u00e1gyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016;7(40):64910\u201364920.27626311"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/139\/2\/article-p344.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/139\/2\/article-p344.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/139\/2\/article-p344.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T10:45:30Z","timestamp":1716029130000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/139\/2\/article-p344.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":37,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2022.12.jns221221","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}